'Bionic Face' Experiments Could Lead to New Treatment Approach for Facial Paralysis
An implantable neuroprosthetic device may one day provide a new approach to restoring more natural facial movement in patients with one-sided facial paralysis (hemifacial palsy), suggests a study in the January issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
Initial experiments in animals show promising results with a "bionic face" approach to facial reanimation – using electrical signals from the uninjured side of the face to trigger muscle movement on the paralyzed side. "Such an approach... would represent a paradigm shift in management" of hemifacial palsy, according to research led by Nate Jowett, MD, of Massachusetts Eye and Ear Infirmary and Harvard Medical School.
Facial Reanimation to Restore Spontaneous Smile after Facial Paralysis
Hemifacial palsy is a "devastating clinical condition" leading to functional, aesthetic, and communication problems. While reconstructive surgery approaches such as nerve and muscle transfers can restore some facial movement, these techniques have important shortcomings. For example, while patients may regain some ability to smile, it requires a conscious effort to do so.
Dr. Jowett and coauthors report the development and "proof of principle" of a new technique using functional electrical stimulation to restore motion of the face in hemifacial palsy. To evoke more natural and appropriate movements, the stimulation of the paralyzed side is linked to the electrical activity on the unaffected side to produce paired muscle contractions.
The researchers implanted tiny electrically-shielded cuff electrodes around the facial nerve of rats with experimentally induced hemifacial palsy. Electrical stimulation was delivered to produce eye blinks and whisker movements of varying durations and amplitudes. Movements were evoked by linking stimulation of the paralyzed side driven to movements on the uninjured side. The "paired muscle contractions" produce more natural, normal-appearing movements. The authors note that most facial expressions, especially positive ones, are symmetrical.
But for functional electrical stimulation to work, the researchers had to overcome another challenge: suppressing undesired/involuntary facial movements caused by impulses from regrown nerves or surgically transferred nerves. This was done by concurrently applying high-frequency alternating current to block the nerve signals causing undesired movements. This technique provided "effective and reversible facial nerve blockade," with no apparent harmful effects.
Previous studies have reported the basic concept of using signals from the healthy side of the face to drive functional electrical stimulation of paralyzed facial muscles. But the new study addresses some key technical challenges affect the long-term success of this approach – including providing more natural, spontaneous smile and other facial movements while blocking unwanted, involuntary movements.
While the preliminary experiments in rats are encouraging, there's a long way to go before the "bionic face" can be refined enough for testing in human patients with hemifacial palsy. The authors plan further studies to develop a miniaturized, fully implantable neuroprosthetic device for hemifacial reanimation.
"Though the ultimate goal of reanimation is to restore dynamic motion of the entire facial musculature, restoration of three symmetric facial movements alone – brow elevation, blink, and smile – would dramatically improve outcomes," Dr. Jowett and coauthors write. They believe that the combination of proximal neural blockade with distal functional electrical stimulation might also prove useful in treatment of other peripheral nerve disorders, such as spastic disorders (abnormal muscle contractions) or neuropathic conditions (nerve pain).
Click here to read "Toward the Bionic Face: A Novel Neuroprosthetic Device Paradigm for Facial Reanimation Consisting of Neural Blockade and Functional Electrical Stimulation"
Article: "Toward the Bionic Face: A Novel Neuroprosthetic Device Paradigm for Facial Reanimation Consisting of Neural Blockade and Functional Electrical Stimulation" (doi: 10.1097/PRS.0000000000005164)
About Plastic and Reconstructive Surgery
For more than 70 years, Plastic and Reconstructive Surgery® has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.
The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 8,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 93 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.